Somewhat Positive Press Coverage Somewhat Unlikely to Impact Sunesis Pharmaceuticals (SNSS) Share Price

News headlines about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.4601722318042 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the headlines that may have effected Accern’s analysis:

Sunesis Pharmaceuticals traded up $0.08, reaching $2.19, during midday trading on Monday, reports. The stock had a trading volume of 330,000 shares, compared to its average volume of 250,022. The firm has a market capitalization of $72.52 million, a price-to-earnings ratio of -1.51 and a beta of 1.74. Sunesis Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $7.69.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.06. The firm had revenue of $0.24 million during the quarter. equities analysts predict that Sunesis Pharmaceuticals will post -0.92 earnings per share for the current year.

A number of equities analysts recently issued reports on SNSS shares. ValuEngine lowered Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Cantor Fitzgerald restated a “hold” rating and issued a $4.00 target price on shares of Sunesis Pharmaceuticals in a research note on Thursday, March 8th. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 14th. Finally, Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 8th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Sunesis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $4.12.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Insider Buying and Selling by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply